Jaguar Animal Health Exhibits Neonorm Foal at American Association of Equine Practitioners Annual Convention
Jaguar Also Hosted a Dinner Discussion Gathering During AAEP with Equine Veterinarian Opinion Leaders in Support of the Company’s Clinical Development Efforts
Founded in 1954, the AAEP has 9,000 members worldwide. The AAEP’s Annual
Neonorm™ Foal is a natural, clinically-tested, non-drug product designed for use as an anti-diarrheal in foals. The product, which acts locally in the gut and is minimally absorbed systemically, contains a proprietary, standardized botanical extract derived from the Croton lechleri tree, which is sustainably harvested.
Jaguar’s dinner gathering of equine opinion leaders took place in
Diarrhea is one of the most common clinical complaints in foals, especially within the first 30 days of life, and to the Company’s knowledge there are currently no commercially available products with anti-secretory properties for foals. The crippling effects of dehydration that often occur as a result of secretory diarrhea in foals can manifest quickly, precipitate adverse health effects and result in death.
“The addressable market for Neonorm™ would be significantly
expanded if we’re able to demonstrate that the product can be used to
address diarrhea in adult horses,” stated
Jaguar launched Neonorm Foal in early 2016 with a nationwide campaign
offering samples. The reception among users of the product has been
overwhelmingly positive, leading to a number of favorable posts from
users on Jaguar’s
Foaling season in the northern hemisphere takes place from January to
July. Jaguar estimates that approximately 300,000 to 360,000 foals are
born in the US each year. Data from the
For more information, please visit www.jaguaranimalhealth.com.
Certain statements in this press release constitute “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. These include statements regarding the Company’s belief that the addressable market for Neonorm™ would be significantly expanded if Jaguar is able to demonstrate that the product can be used to address diarrhea in adult horses, and Jaguar’s intention to develop species-specific formulations of Neonorm™ in six additional target species, formulations of Equilevia™ in horses, and Canalevia™ for cats and dogs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
KCSA Strategic Communications
Garth Russell, 212-896-1250